TENX · Tenax Therapeutics, Inc. · Executive Compensation
$1.63
+0.11 (+7.24%)
At close · Oct 20
Return incl. dividend (before tax)
Market Cap
$56.88M
Shares
37.42M
Volume · Oct 20
1.46M
Avg daily vol (3M)
5.58M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Thomas A. McGauley | Interim Chief Financial Officer | Resigned | 2026-04-22 |
| Thomas R. Staab, II | Chief Financial Officer | Appointed | 2026-04-22 |
| Thomas A. McGauley | principal financial officer and principal accounting officer | Appointed | 2024-12-04 |
| Thomas A. McGauley | Interim Chief Financial Officer | Appointed | 2024-12-04 |
| Lawrence R. Hoffman | Interim Chief Financial Officer | Appointed | 2024-01-12 |
Leadership
- Christopher T. Giordano CEO, Board Member
- Christopher Thomas Giordano CEO, Board Member
- Gerald Proehl Chairman
- Eliot M. Lurier CFO
- Lawrence R. Hoffman CFO, Chief Accounting Officer
- Thomas A. McGauley CFO, Chief Accounting Officer
- Thomas R. Staab, II CFO
- Declan Doogan Board Member
- Gerald T. Proehl Board Member
- June Almenoff Board Member
- Keith Maher Board Member
- Michael Davidson Board Member
- Robyn M. Hunter Board Member
- Steven Boyd Board Member
- Steven J. Boyd Board Member
- Stuart Rich Board Member